VICAL INCORPORATED (NASDAQ:VICL) Files An 8-K Other Events
Item 8.01Other Events

On April 4, 2017, Vical Incorporated entered into a research collaboration agreement with AnGes MG, Inc. (“AnGes”). to the collaboration agreement, AnGes agreed to provide funding for the program up to a specified limit and we agreed to conduct certain preclinical research related to a development program targeting chronic hepatitis B. In exchange for the payment, AnGes will receive an option to negotiate exclusive rights in Japan related to the program. The parties also agreed to share the costs of prosecuting and maintaining intellectual property rights arising from the research program after such costs reach a specified limit.

About VICAL INCORPORATED (NASDAQ:VICL)

Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of life-threatening diseases. The Company has approximately four active, independent, or partnered development programs in the areas of infectious disease including Phase III clinical trial of ASP0113 for prevention of cytomegalovirus (CMV) reactivation in stem cell transplant recipients and Phase II clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients; Phase I/II clinical trial of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2 (HSV-2) infected patients; an ongoing Phase I program of VL-2397 for invasive fungal infections, and completed preclinical program, with an allowed investigational new drug application (IND) using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant.

VICAL INCORPORATED (NASDAQ:VICL) Recent Trading Information

VICAL INCORPORATED (NASDAQ:VICL) closed its last trading session down -0.03 at 2.13 with 34,464 shares trading hands.